TGA investigating potential link between diabetes drug Ozempic and reports of gastro-intestinal side effects

Drug has been used off-label for weight loss leading to a global shortage and usage may come with risks, experts say

• Get our morning and afternoon news emails, free app or daily news podcast

Australia's drug regulator is investigating new reports of potential gastro-intestinal side effects of diabetes turned weight-loss drug Ozempic.

Ozempic, is a drug prescribed as a treatment for type 2 diabetes, but has been widely used off-label for weight loss, causing worldwide shortages, including in Australia. The same drug, branded as Wegovy, is now approved for weight management in Australia, but is not currently available.

Sign up for Guardian Australia's free morning and afternoon email newsletters for your daily news roundup